Mechanism-directed combinational immunotherapies in liver cancer hold promise

作     者：Gregory Marshall Jian Cao 

作者机构：Rutgers Cancer Institute of New JerseyNew BrunswickNJ08901USA Department of MedicineRobert Wood Johnson Medical SchoolRutgersThe State University of New JerseyNew BrunswickNJ08901USA 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2023年第20卷第11期

页      面：1395-1397页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by NJCCR fellowship COCR23PRF035(to GM)and the National Cancer Institute grant R01CA272578(to JC) 

主　　题：cancer mortality hepatitis 

摘      要：Hepatocellular carcinoma(HCC)is the most prevalent form of primary liver cancer,and it is the third leading cause of cancer-related mortality *** primary causes of HCC include chronic infections with hepatitis B virus(HBV)or hepatitis C virus(HCV)and alcoholic steatohepatitis(ASH)or nonalcoholic steatohepatitis(NASH).